Viatris Inc (VTRS) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH – Nov. 5, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results." exhibit |
| Q3 FY2026 | "Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio upon expected closing by the end of November.” [1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 adjusted EBITDA or adjusted EPS guidance." exhibit |
| Q3 FY2026 | "U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $2.025 billion and $2.1 billion, with a midpoint of approximately $2.0625 billion. 2026 financial guidance ranges as provided on November 5, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. 2026 financial guidance ranges also exclude any contribution from the planned acquisition of Pacira BioSciences." exhibit |
| Q3 FY2026 | "Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information. 2 Third-Quarter Results Three Months Ended September 30, (Unaudited; in millions, except %s and per share amounts) 2026 2025 Reported Change Operational Change (1) (2) Total Revenues $ 3,749.5 $ 3,759.9 —% —% Total Net Sales $ 3,734.7 $ 3,747.5 —% —% Developed Markets 2,215.9 2,255.6 (2)% (1)% Emerging Markets 529.1 570.4 (7)% (6)% JANZ 287.1 306.3 (6)% (5)% Greater China 702.6 615.2 14% 10% Net Sales by Product Category Brands $ 2,461.4 $ 2,436.8 1% 1% Generics 1,273.3 1,310.7 (3)% (3)% U.S. GAA" exhibit |
| Q3 FY2026 | "The Company generated approximately $115 million in new product revenues (approximately $287 million for the year) and now expects to deliver approximately $450 million in new product revenues in full-year 2026." exhibit |
| Q2 FY2026 | "Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH – August 6, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results." exhibit |
| Q2 FY2026 | "In addition, we further strengthened our balance sheet and reduced our gross leverage ratio to 2.9x.” [1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 Adjusted EBITDA or Adjusted EPS guidance." exhibit |
| Q2 FY2026 | "U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.9 billion and $2.1 billion, with a midpoint of approximately $2.0 billion. 2026 financial guidance ranges as provided on August 6, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted." exhibit |
| Q2 FY2026 | "Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information." exhibit |
| Q2 FY2026 | "The Company currently anticipates the impact of product supply disruptions to be between $100 million and $150 million to total revenues in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VTRS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VTRS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/VTRS/"><img src="https://veritasdata.dev/embed/VTRS.svg" alt="VTRS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/VTRS/)
Script
<script async src="https://veritasdata.dev/embed/VTRS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VTRS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.